Garcia-Manero, G., Porta, M. G. D., Zeidan, A. M., Komrokji, R. S., Pozharskaya, V., Lai, Y., Menezes, D. E. L. D., Guerrero, M. U., Farazi, T. A., Miteva, D., Aggarwal, B., Kalsekar, S., Valcárcel, D., Fenaux, P., Shortt, J., Platzbecker, U., Santini, V. (2026). Updated overall survival (OS) and long-term transfusion-independence (TI) from the phase 3 COMMANDS trial in erythropoiesis-stimulating agent (ESA)–naive patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.6566